24 30 19 32 19 39 ten 26 17 27 19 29 20 34 21 33 19 44 29 210 132 209 130 203 144 191 150 196 146 199 144 202 138 193 148 191 151 200 138 200 140 220 124 207 135 197 142 OR 95 CI Quartile 3 No. of No. of Circumstances Controls 27 19 33 23 37 22 38 15 29 15 38 19 35 14 32 23 37 16 38 21 31 18 36 21 33 24 21 19 189 156 197 145 197 146 206 137 206 139 200 143 201 142 197 146 196 147 194 151 207 132 204 139 207 142 203 142 OR 95 CI Quartile four No. of No. of Cases Controls 34 15 39 18 35 19 33 14 34 16 35 16 36 17 32 27 30 20 26 24 28 23 28 ten 38 24 26 10 217 123 212 130 204 132 196 144 191 148 191 147 188 151 228 116 211 130 217 126 one hundred 146 189 152 204 135 212 132 OR 95 CI Ptrend PinteractionFatty Acids n-3 PUFAs -Linolenic acid Eicosatrienoic acid Eicosapentaenoic acid Docosapentaenoic acid Docosahexaenoic acid EPA + DHA Total n-3 n-6 PUFAs Linoleic acid -Linolenic acid Eicosadienoic acid Dihomo– linolenic acid Arachidonic acid Docosadienoic acidGG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA GG GA/AA1.Referent1.31 0.77, 2.22 1.45 0.80, 2.61 0.92 0.52, 1.62 1.36 0.75, two.48 1.25 0.71, 2.20 1.39 0.75, 2.55 0.96 0.55, 1.69 1.28 0.73, 2.26 1.88 1.09, three.24 1.55 0.84, two.84 1.39 0.79, 2.47 1.24 0.65, two.34 1.46 0.83, 2.56 1.32 0.70, 2.51 1.61 0.93, two.78 0.56 0.26, 1.20 0.1097871-14-1 structure 78 0.45, 1.35 0.70 0.37, 1.30 0.74 0.43, 1.27 0.83 0.46, 1.52 0.76 0.45, 1.28 0.80 0.44, 1.43 1.11 0.65, 1.89 1.24 0.68, two.29 1.38 0.78, two.44 1.29 0.68, 2.47 1.31 0.81, two.14 1.19 0.69, two.1.08 0.61, 1.91 0.92 0.49, 1.71 1.18 0.69, 2.05 1.18 0.65, 2.14 1.47 0.84, two.55 1.19 0.64, 2.22 1.34 0.80, 2.25 0.83 0.43, 1.60 1.37 0.77, 2.45 1.05 0.53, 2.08 1.74 1.01, 3.02 1.25 0.66, two.38 1.64 0.94, two.87 0.92 0.46, 1.84 1.31 0.74, two.30 1.27 0.69, 2.35 1.04 0.62, 1.74 0.61 0.32, 1.16 1.17 0.71, 1.93 0.80 0.45, 1.44 0.80 0.48, 1.34 0.74 0.40, 1.37 1.29 0.76, 2.19 1.11 0.61, two.03 1.44 0.81, 2.54 1.50 0.81, 2.77 0.60 0.34, 1.07 0.80 0.44, 1.1.16 0.67, 2.01 0.96 0.95 0.48, 1.87 0.80 1.39 0.82, two.37 0.16 1.4,6-Dibromopyridin-2-amine structure 06 0.PMID:23460641 56, two.01 0.21 1.25 0.71, two.20 0.27 1.11 0.58, 2.14 0.95 1.21 0.71, two.06 0.24 0.72 0.37, 1.41 0.026 1.64 0.93, two.90 0.33 1.09 0.55, 2.15 0.17 1.66 0.95, 2.92 0.07 1.06 0.54, 2.ten 0.15 1.70 0.97, 2.98 0.07 1.10 0.56, two.14 0.033 1.22 0.69, 2.16 0.96 two.04 1.16, 3.74 0.017 0.78 0.46, 1.33 0.77 0.86 0.47, 1.56 0.07 0.68 0.39, 1.17 0.29 1.12 0.64, 1.99 0.06 0.73 0.43, 1.25 0.33 0.85 0.48, 1.51 0.66 1.03 0.59, 1.82 0.62 0.49 0.23, 1.07 0.024 1.69 0.97, 2.94 0.05 1.67 0.90, three.10 0.027 0.70 0.41, 1.22 0.06 0.46 0.22, 0.97 0.0.1.01 0.54, 1.89 1.00 Referent0.0.68 0.35, 1.35 1.00 Referent0.0.96 0.48, 1.93 1.00 Referent0.1.49 0.82, 2.70 1.00 Referent0.1.86 1.00, three.44 1.00 1.00 Referent Referent0.011 0.1.97 1.07, 3.63 two.21 1.23, 4.00 1.00 ReferentSerum Phospholipid Fatty Acids and Prostate Cancer0.1.14 0.59, 2.18 1.00 1.00 1.00 Referent Referent Referent 1.34 0.76, two.0.42 0.09 0.0.62 0.32, 1.0.70 0.38, 1.30 1.00 1.00 Referent Referent0.036 0.1.36 0.76, 2.41 0.72 0.34, 1.53 1.00 ReferentDocosatetraenoic acidGG GA/AA0.0.89 0.49, 1.Table continues1114 Cheng et al.Abbreviations: CARET, Carotene and Retinol Efficacy Trial; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; OR, odds ratio; PUFA, polyunsaturated fatty acid. a Multivariate adjustment for age at enrollment (continuous), race (white, black, others), CARET randomization assignment (retinol plus -carotene, placebo), family history of prostate cancer in first-degree rela.